• 1
    Carreno BM, Carter LL, Collins M. Therapeutic opportunities in the B7/CD28 family of ligands and receptors. Curr Opin Pharmacol 2005; 5:42430.
  • 2
    Vincenti F. Antibodies come back to the forefront in transplantation. Clin J Am Soc Nephrol 2006; 1:399.
  • 3
    Vincenti F, Luggen M. T cell costimulation a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med 2007; 58:34758.
  • 4
    Czuczman MS, Thall A, Witzig TE et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005; 23:43908.
  • 5
    Gottlieb AB, Kang S, Linden KG et al. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol 2004; 111:2837.
  • 6
    Huxley P, Sutton DH, Debnam P et al. High-affinity small molecule inhibitors of T cell costimulation: compounds for immunotherapy. Chem Biol 2004; 11:16518.
  • 7
    Wakem P, Burns RP Jr, Ramirez F et al. Allergens and irritants transcriptionally upregulate CD80 gene expression in human keratinocytes. J Invest Dermatol 2000; 114:108592.
  • 8
    Nuriya S, Yagita H, Okumura K, Azuma M. The differential role of CD86 and CD80 co-stimulatory molecules in the induction and the effector phases of contact hypersensitivity. Int Immunol 1996; 8:91726.
  • 9
    Xu H, Heeger PS, Fairchild RL. Distinct roles for B7-1 and B7-2 determinants during priming of effector CD8+ Tc1 and regulatory CD4+ Th2 cells for contact hypersensitivity. J Immunol 1997; 159:421726.
  • 10
    Nasir A, Ferbel B, Salminen W, Barth RK, Gaspari AA. Exaggerated and persistent cutaneous delayed-type hypersensitivity in transgenic mice whose epidermal keratinocytes constitutively express B7-1 antigen. J Clin Invest 1994; 94:8928.
  • 11
    Gaspari AA, Burns R, Nasir A, Ramirez D, Barth RK, Haidaris CG. CD86 (B7-2), but not CD80 (B7-1), expression in the epidermis of transgenic mice enhances the immunogenicity of primary cutaneous Candida albicans infections. Infect Immun 1998; 66:44409.
  • 12
    Davidsen J, Rosenkrands I, Christensen D et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate) – a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005; 1718:2231.
  • 13
    June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 1987; 7:447281.
  • 14
    Stanczyk J, Ospelt C, Gay S. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr Opin Rheumatol 2008; 20:25762.
  • 15
    Ikemizu S, Gilbert RJ, Fennelly JA et al. Structure and dimerization of a soluble form of B7-1. Immunity 2000; 12:5160.
  • 16
    Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004; 21:40113.
  • 17
    Lenschow DJ, Zeng Y, Hathcock KS et al. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 1995; 60:11718.
  • 18
    Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 1996; 93:1396772.
  • 19
    Yamada A, Kishimoto K, Dong VM et al. CD28-independent costimulation of T cells in alloimmune responses. J Immunol 2001; 167:1406.
  • 20
    Srinivasan M, Eri R, Zunt SL, Summerlin DJ, Brand DD, Blum JS. Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent. Arthritis Rheum 2007; 56:498508.
  • 21
    Prud'homme GJ, Chang Y, Li X. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Hum Gene Ther 2002; 13:395406.
  • 22
    Bas E, Recio MC, Giner RM et al. Demethylnobiletin inhibits delayed-type hypersensitivity reactions, human lymphocyte proliferation and cytokine production. Br J Pharmacol 2007; 152:127282.
  • 23
    Cole SW, Kemeny ME, Weitzman OB, Schoen M, Anton PA. Socially inhibited individuals show heightened DTH response during intense social engagement. Brain Behav Immun 1999; 13:187200.
  • 24
    Ramos G, Limon-Flores AY, Ullrich SE. Dermal exposure to jet fuel suppresses delayed-type hypersensitivity: a critical role for aromatic hydrocarbons. Toxicol Sci 2007; 100:41522.
  • 25
    Cordoba Castro F, Wieczorek G, Preussing E, Bigaud M. Modeling of delayed type hypersensitivity (DTH) in the non-human primate (NHP). Drug Disc Today Dis Models 2008; 5:6371.
  • 26
    Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MH, Akbar AN. Mantoux test as a model for a secondary immune response in humans. Immunol Lett 2006; 107:93101.
  • 27
    Reed JR, Vukmanovic-Stejic M, Fletcher JM et al. Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med 2004; 199:143343.